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Association of Parental Obesity and Diabetes Mellitus With
Circulating Adipokines in Nonobese Nondiabetic Offspring
Justin P. Zachariah, MD, MPH;* Rene Quiroz, MD, MPH;* Danielle Enserro, PhD; Charlotte Andersson, MD, PhD; John F. Keaney, Jr, MD;
Lisa M. Sullivan, PhD; Ramachandran S. Vasan, MD
Background-—Adipokines are implicated in the development of obesity-related traits. We hypothesized that nonobese participants
without diabetes mellitus (DM) whose parents were obese or had DM would have altered circulating adipokines compared with
those without parental history of these conditions.
Methods and Results-—Participants in the community-based Framingham Third Generation cohort who were not obese (body
mass index <30) and not diabetic with both parents in the Framingham Offspring cohort were included in this analysis (n=2034,
mean age 40 years, 54% women). Circulating concentrations of fetuin A, RBP4 (retinol binding protein 4), FABP4 (fatty acid binding
protein 4), leptin, LEP-R (leptin receptor), and adiponectin were assayed. Parental DM was deﬁned as occurring before age
60 years, and obesity was deﬁned as body mass index ≥30 before age 60 years. General estimating equations were used to
compare concentrations of adipokines among participants with 0, 1, or 2 parents affected by obesity or DM (separate analyses for
each), adjusting for known correlates of adipokines. Overall, 44% had at least 1 parent who was obese and 15% had parents with
DM. Parental obesity was associated with higher serum levels of FABP4 and LEP-R in their offspring (P=0.02 for both). Parental DM
was associated with lower adiponectin but higher RBP4 concentrations in offspring (P≤0.02 for both).
Conclusions-—In our community-based sample, a parental history of DM or obesity was associated with an altered adipokine
proﬁle in nonobese nondiabetic offspring. Additional studies are warranted to evaluate whether such preclinical biomarker
alterations presage future risk of disease. ( J Am Heart Assoc. 2017;6:e004973. DOI: 10.1161/JAHA.116.004973.)
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O besity predisposes to diabetes mellitus (DM), dyslipi-demia, and hypertension1 and is associated with
increased mortality.2 The Centers for Disease Control and
Prevention estimate that 1 in 3 Americans is obese, and
nearly 60% are overweight.3 Epidemiologic studies have
shown that obesity and DM both cluster within families.4–6
Consequently, the characterization of biological mediators of
the transgenerational transmission of obesity and related
traits like DM may help identify the highest risk persons.
Adipose tissue is now understood to be biologically
active including the production of circulating compounds
(called adipokines) such as leptin, its counterregulatory
circulating receptor (LEP-R [leptin receptor]), adiponectin,
fetuin A, FABP4 (fatty acid binding protein 4), and RBP4
(retinol binding protein 4). Adipokines appear to partially
mediate the association between excess adiposity and
hyperglycemia, hyperinsulinemia, sympathetic activity,
inﬂammation, and vascular measures.7,8 In addition, there
is evidence that concentrations of several of these
biomarkers are heritable traits.9,10 These observations raise
the possibility that parental obesity and/or DM may be
associated with altered levels of selected adipokine
biomarkers in nonobese nondiabetic offspring, antedating
the development of obesity and related traits. We hypoth-
esized that among nonobese offspring, those with parental
obesity would have higher circulating levels of fetuin A,
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FABP4, RBP4, and LEP-R but lower levels of leptin and
adiponectin (compared with those without parental obesity).
We postulated that a similar pattern would be seen in
nondiabetic children of parents with versus without DM. We
further hypothesized that offspring adipokine concentrations
would change in stepwise fashion with the number of
parents with obesity or DM.
Methods
Study Sample
The design and selection criteria of the Framingham Heart
Study Third Generation Cohort are detailed elsewhere.11 For
the present investigation, participants attending the ﬁrst
examination cycle (2002–2005) and who had both parents
in the Framingham Offspring Cohort were eligible. Given the
high lifetime risk of developing obesity,12 we deﬁned
parental obesity as a body mass index (BMI) ≥30 (calcu-
lated as kg/m2) occurring before age 60 years. Parental
DM was also deﬁned as occurring before age 60 years. Of
4095 participants in attendance at examination 1, exclu-
sions were made because of missing parental history of
disease (n=904), missing adipokine data (n=161), prevalent
obesity (n=948), and prevalent DM (use of antiglycemic
agents or fasting plasma glucose ≥126 mg/dL; n=48). The
institutional review board of Boston University approved the
study protocol, and all participants provided informed
consent.
Clinical Evaluation and Blood Adipokine
Measurements
Participants underwent laboratory assessment of risk factors and
a routine medical history and standardized physical examination
(including blood pressure [BP] measurement and anthropometry)
at each Framingham Heart Study examination. After the partic-
ipant had rested in a seated position for 5 minutes, a physician
measured the BP with an appropriately sized cuff on the left arm
using a mercury column sphygmomanometer. The average of 2
readings constituted the examination BP. Fasting levels of plasma
high-density lipoprotein cholesterol, triglycerides, and glucose
were measured using standardized assays. Self-reported use of
cigaretteswithin theyear preceding thebaselineexaminationwas
deﬁned as current smoking.
At the baseline examination, participants had phlebotomy
performed after an overnight fast and after they had rested for 5
to 10 minutes in a supine position. Specimens were stored at
80°Cwithout freeze–thaw cycles until assayed. Plasma levels
of leptin, LEP-R, RBP4, and adiponectin were measured using
ELISA, whereas fetuin A and FABP4 were measured using
sandwich ELISA. Baseline fasting plasma glucose and insulin
levels were measured during examination cycle 1. The average
interassay coefﬁcients of variation for all adipokines were <5%.
Statistical Analyses
Adipokine concentrations were natural logarithmically trans-
formed to normalize their skewed distributions. To compare
adipokine levels between Third Generation nonobese, nondia-
betic participants with parental obesity or DM versus those with
unaffected parents, we used generalized estimating equa-
tion models accounting for familial correlations. In addition, we
adjusted for known adipokine correlates including the following
characteristics of Third Generation participants: age, sex, BMI,
systolic and diastolic BP, hypertension treatment, DM, total/
high-density lipoprotein cholesterol ratio, and smoking.10
Parental disease was modeled as an ordinal variable with
0, 1, or 2 affected parents. In multivariable models, BMI was
treated as a continuous variable. We examined prespeciﬁed
interactions by sex that were signiﬁcant for RBP4 and LEP-R
(P<0.05 for each), and so sex-speciﬁc results are presented;
interaction term for continuous BMI was not signiﬁcant, so
results are presented for pooled BMI strata. A 2-sided P<0.05
was considered statistically signiﬁcant, and SAS 9.3 (SAS
Institute) was used for all analyses.
Results
Clinical characteristics of our study sample, including mean
concentrations of circulating adipokine levels, are shown in
Clinical Perspective
What Is New?
• Given the familial clustering of obesity-related traits like
metabolic syndrome, we examined the association between
parent obesity or diabetes mellitus and adipokine levels in
nonobese offspring as possible mediators of familial
aggregation.
• Parental obesity was associated with higher FABP4 and LEP-
R (leptin receptor) in adult offspring.
• Parental diabetes mellitus was associated with lower
adiponectin but higher RBP4.
What Are the Clinical Implications?
• With future investigation, circulating adipokines may serve
to identify offspring at high risk of transgenerational
transmission of metabolic syndrome.
• Future studies may also explore the role of adipokines in the
transgenerational transmission of metabolic syndrome
traits.
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Table 1. Men differed from women in BMI, BP, lipids, and
several adipokine levels, whereas prevalence of parental
obesity and DM was similar between the 2 sexes. Overall,
44% of participants (n=900) had at least 1 obese parent
(Table 1), and 15% (n=309) had at least 1 parent with DM.
Both obesity and DM occurred in at least 1 parent in 153
participants.
Association of Parental Obesity or DM and
Offspring Adipokine Levels
The clinical characteristics in men and women stratiﬁed by
the presence or absence of parental obesity are shown in
Table 2. Clinical characteristics for men and women with or
without a history of parental DM before age 60 are shown in
Table 3. In multivariable-adjusted models, parental obesity
before age 60 years was associated with higher offspring
circulating FABP4 and LEP-R concentrations (Table 4 and
Figure 1). Sex-stratiﬁed multivariable-adjusted analyses were
performed that demonstrated women with parental obesity
had higher serum levels of RBP4 (men: 0.007 [95%
conﬁdence interval (CI), 0.03 to 0.02]; women: 0.02 [95%
CI, 0.002 to 0.05]; interaction P=0.047) and LEP-R (men:
0.01 [95% CI, 0.04 to 0.05]; women: 0.08 [95% CI, 0.03–
0.12]; interaction P=0.01). Similarly, in multivariable-
adjusted models, parental DM was associated with higher
RBP4 but lower adiponectin concentrations (Table 2 and
Figure 2). In sex-speciﬁc analyses, parental DM was asso-
ciated with higher RBP4 concentrations in women (men:
0.02 [95% CI, 0.0 to 0.06]; women: 0.06 [95% CI, 0.02–
0.1]; interaction P=0.03).
Discussion
In our moderate-sized, community-based sample of young to
middle-aged adult participants, parental history of obesity or
DM was associated with an altered adipokine proﬁle in
nonobese nondiabetic offspring. Parental obesity was asso-
ciated with higher serum levels of FABP4 and LEP-R, whereas
parental history of DM was associated with higher circulating
RBP4 but lower adiponectin concentrations. Sex modiﬁed the
effect of parental status on adipokine concentrations. These
associations were found to be robust even after adjustment
for BMI. Taken together, these ﬁndings are consistent with
the notion of a transgenerational role linking family history of
obesity and DM to key antecedents of these traits in
nonobese nondiabetic offspring.
Offspring FABP4, Leptin, and LEP-R and Parental
Obesity
We observed a signiﬁcant association between serum
FABP4 and parental history of obesity before age 60 years.
We are unaware of previous reports regarding relations of
blood FABP4 and familial history of obesity. FABP4 is
produced in adipocytes, constituting 1% of soluble proteins
in adipose tissue.13 Expression of FABP4 is highly induced
during adipocyte differentiation and is transcriptionally
controlled by key regulators including insulin.14 After oral
glucose tolerance testing, insulin levels increase to inhibit
Table 1. Descriptive Characteristics of Study Sample
Characteristics Women (n=1103) Men (n=931)
Clinical characteristics
Age, y 408 408
Body mass index,
kg/m2
23.43.0 25.92.5
Systolic BP, mm Hg 11013 11912
Diastolic BP, mm Hg 719 779
Antihypertensive
medication, %
4.3 6.8
Serum total
cholesterol
18232 19338
Serum high density
lipoprotein
6316 4813
Lipid lowering
medication, %
3.5 10.9
Smokers, % 14.1 15.0
Parental disease, n (%)*
Obesity (BMI ≥30)
0 parents 605 (54.8) 529 (56.8)
1 parent 409 (37.1) 327 (35.1)
2 parents 89 (8.1) 75 (8.1)
DM before age 60 y
0 parents 936 (84.9) 789 (84.8)
1 parent 159 (14.4) 138 (14.8)
2 parents 8 (0.7) 4 (0.4)
Circulating biomarkers
RBP4, lg/mL 36.5 (30.5, 44.7) 43.4 (37.0, 49.9)
FABP4, ng/mL 16.1 (12.1, 21.4) 13.7 (10.1, 17.3)
Fetuin A, lg/mL 421.9 (316.0,
548.8)
408.3 (318.2,
515.9)
Leptin, pg/mL 9349.1 (5045.0,
15 448.6)
3336.2 (2010.2,
5296.6)
LEP-R, ng/mL 20.1 (13.6, 26.1) 19.2 (12.7, 24.8)
Adiponectin, ng/mL 10 826.5
(7507.7,
15 075.8)
5482.3 (3620.9,
8244.2)
Values are meanSD and adipokine concentrations are expressed as median (Q1, Q3)
unless indicated. BMI indicates body mass index; BP, blood pressure; DM, diabetes
mellitus; LEP-R, leptin receptor.
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lipolysis and concomitant FABP4 levels drop.15 FABP4
appears to be required for adipocyte maturation.16 Conse-
quently, in participants with family history of obesity,
inherited higher FABP4 may interact with a milieu of insulin
resistance and enhanced lipolysis to favor obesity-related
traits in offspring.
Table 2. Clinical Characteristics of Participants With and Without Parental History of Obesity Before Age 60 Years
Women Men
No Parental Obesity (n=605) ≥1 Parent With Obesity (n=498) No Parental Obesity (n=529) ≥1 Parent With Obesity (n=402)
Age, y 418 387 418 398
Smokers, % 11.7 16.9 12.9 17.7
BMI, kg/m2 22.92.9 24.03.0 25.42.6 26.42.4
SBP, mm Hg 11013 11013 11912 11912
DBP, mm Hg 719 719 789 779
Total cholesterol 18333 18132 19334 19342
HDL 6416 6215 4812 4813
Antihypertensive medication, % 4.3 4.2 7.0 6.4
Lipid-lowering medication, % 3.8 3.0 10.6 11.2
RBP4, lg/mL 36 (30, 43) 38 (31, 46) 44 (37, 50) 43 (37, 50)
FABP4, ng/mL 16 (12, 21) 17 (12, 23) 13 (10, 17) 14 (11, 18)
Fetuin A, lg/mL 418 (316, 545) 429 (318, 555) 408 (312, 510) 408 (330, 517)
Leptin, pg/mL 8709 (4698, 14 734) 10 133 (5882, 16 363) 3155 (1940, 4939) 3537 (2172, 5744)
LEP-R, ng/mL 20 (13, 26) 20 (14, 26) 20 (13, 25) 19 (13, 25)
Adiponectin, ng/mL 11 487 (8112, 15 214) 10 278 (6821, 14 874) 5513 (3657, 8244) 5454 (3611, 8201)
Values are meanSD and concentrations are expressed as median (Q1, Q3) unless indicated. BMI indicates body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein;
LEP-R, leptin receptor; SBP, systolic blood pressure.
Table 3. Clinical Characteristics of Participants With and Without a Parental History of DM Before Age 60 Years
Women Men
No Parental DM (n=936) ≥1 Parent With DM (n=167) No Parental DM (n=789) ≥1 Parent With DM (n=142)
Age, y 408 398 408 407
Smokers, % 11.1 30.5 14.5 17.6
BMI, kg/m2 23.33.0 23.83.2 25.82.5 26.32.6
SBP, mm Hg 11013 11214 11912 12012
DBP, mm Hg 719 7110 779 798
Total cholesterol 18132 18633 19338 19235
HDL 6316 6217 4812 4714
Antihypertensive medication, % 3.9 5.9 5.8 12.0
Lipid lowering medication, % 3.6 2.4 9.6 17.6
RBP4, lg/mL 36 (30, 44) 39 (33, 47) 43 (37, 50) 43 (37, 52)
FABP4, ng/mL 16 (12, 21) 17 (13.5, 24) 14 (10, 17) 15 (11, 19)
Fetuin-A, lg/mL 418 (314, 545) 472 (337, 571) 411 (321, 516) 397 (318, 512)
Leptin, pg/mL 9021 (4935, 14 926) 10 531 (5882, 18 753) 3317 (1980, 5222) 3467 (2172, 5982)
LEP-R, ng/mL 20 (13, 26) 19 (15, 25) 19 (12, 24) 19 (14, 26)
Adiponectin, ng/mL 11 010 (7748, 15 156) 9468 (6502, 14 195) 5694 (3796, 8438) 4497 (3166, 6814)
Values are meanSD and concentrations are expressed as median (Q1, Q3) unless indicated. BMI indicates body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL,
high-density lipoprotein; LEP-R, leptin receptor; SBP, systolic blood pressure.
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Leptin is a key long-term energy homeostasis signal with
higher energy status marked by lower circulating leptin
concentrations.17,18 Leptin is well described to affect feeding
behaviors and feeding state, likely mediated through its direct
central nervous system effects. Circulating LEP-R binds to
leptin and reduces its bioavailability.17,19 Both markers have
been linked to BMI and fat distribution.20 In obesity,
paradoxical elevation of leptin occurs due to end-organ leptin
resistance17,21; therefore the observed relationship between
parental obesity history and higher LEP-R suggests an
intriguing hypothesis about the counterregulatory role of
LEP-R in affected participants. Higher LEP-R would reduce free
circulating leptin and consequent satiety signaling, which in
turn could induce higher energy intake. Soluble LEP-R is
upregulated by 20-fold in Zucker diabetic obese rats, which
may lead to less circulating leptin and consequently less
satiety signaling and more calorie intake, perhaps implicating
LEP-R in the obesity phenotype of these rats.22
Offspring RBP4 Levels and Parental DM Status
We observed that elevated serum levels of RBP4 were
associated with parental history of diabetes mellitus. RBP4 is
a transport protein highly expressed in liver and adipose
Table 4. Adipokines and Parental History of Obesity or DM Before Age 60
Parental Obesity Parental DM
Age/Sex-Adjusted Multivariable-Adjusted Age/Sex-Adjusted Multivariable-Adjusted
Estimate (SE) P Value Estimate (SE) P Value Estimate (SE) P Value Estimate (SE) P Value
RBP4 0.0189 (0.0098) 0.05 0.0098 (0.0097) 0.31 0.0563 (0.0170) 0.001 0.0415 (0.0163) 0.01
FABP4 0.0945 (0.0167) <0.001 0.0344 (0.0147) 0.02 0.0829 (0.0270) 0.002 0.0372 (0.0232) 0.11
Fetuin A 0.0005 (0.0144) 0.97 0.0029 (0.0147) 0.84 0.0247 (0.0231) 0.29 0.0225 (0.0235) 0.34
Leptin 0.1196 (0.0286) <0.001 0.0370 (0.0225) 0.10 0.1096 (0.0516) 0.03 0.0255 (0.0366) 0.49
LEP-R 0.0107 (0.0183) 0.56 0.0407 (0.0180) 0.02 0.0008 (0.0307) 0.98 0.0135 (0.0296) 0.65
Adiponectin 0.0329 (0.0250) 0.19 0.0134 (0.0239) 0.57 0.1298 (0.0417) 0.002 0.0945 (0.0398) 0.02
Adipokines modeled as continuous, natural logarithm–transformed variables with estimates indicating increase in mean transformed adipokine concentration for each additional parent
with obesity or DM (separate analyses for each). Parental disease modeled as an ordinal variable taking on the values of 0, 1, or 2 parents with condition before age 60. Models were
adjusted ﬁrst for age and sex. The multivariable model was adjusted for age, sex, body mass index, systolic BP, diastolic BP, BP treatment, ratio of total/high-density lipoprotein
cholesterol, and smoking status. BP indicates blood pressure; DM, diabetes mellitus; LEP-R, leptin receptor.
Figure 1. FABP4 and LEP-R (leptin receptor) levels expressed as multivariable adjusted least squares geometric mean and 95% conﬁdence
interval error bars (y-axis) according to the presence or absence of parental obesity before age 60 years (x-axis).
DOI: 10.1161/JAHA.116.004973 Journal of the American Heart Association 5
Parental Obesity and Offspring Adipokines Zachariah et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
ugust 31, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
tissue.23 Overexpression of RBP4 results in insulin resistance,
and knockout leads to enhanced insulin sensitivity.24,25 A
potential association between RBP4 and type 2 DM was
initially described in animal models.26 Subsequent work in
humans shows that in nonobese normoglycemic participants
with at least 1 ﬁrst-degree relative with type 2 DM, higher
RBP4 serum levels were associated with fasting insulin levels.
Higher serum RBP4 levels were associated with a poorer rate
of glucose disposal, adjusted for age and BMI. Other data
from persons before and after modest weight loss suggest
that RBP4 may not play a key role in obesity or glucose
regulation in humans.27 Nonetheless, our ﬁndings suggest
that circulating alterations in RBP4 concentrations may be
one of several plausible mechanisms for the potential
transgenerational transmission of DM.10
Offspring Adiponectin Levels and Parental DM
Status
We observed that lower levels of serum adiponectin in
offspring were associated with parental diabetes mellitus.
Adiponectin is the most abundant protein secreted by
adipose tissue, and plasma levels are correlated negatively
with adiposity and type 2 DM.9 Previous work on the link
between family history of DM and adiponectin is conﬂict-
ing.28,29 Another cohort of nearly 6000 healthy Korean men
and women also found family history of DM was associated
with lower adiponectin levels.30 Discrepant ﬁndings may
have been due in part to a nonstandardized deﬁnition of
family history, geographic or ethnic background and age
differences in samples evaluated, and cross-sectional versus
longitudinal design.
Limitations and Strengths
Limitations, as with any cross-sectional study, are that we
cannot assess the causality of any observed association. Our
sample consisted of mostly white participants, so generaliz-
ability to other ethnicities is limited. Sex-stratiﬁed analyses
relating RBP4 to parental obesity or DM status yielded
conﬁdence intervals that were overlapping in men versus
women (likely due to small sample sizes of individual strata)
despite the statistically signiﬁcant sex interaction term.
Moreover, regression coefﬁcients in our analyses were
numerically small, often due to the scales of measurement
for adipokines. In addition, we did not correct for multiple
statistical testing; as such, our ﬁndings should be viewed as
hypothesis generating and warrant replication in future
studies. The strengths of this study include the community-
based sample, detailed information on parental obesity and
DM occurrence, and the measurement of a comprehensive
panel of adipokines.
Our observations of a moderate-sized community-based
sample of young to middle-aged adults indicate a transgen-
erational association between parental history of obesity or
DM and circulating levels of key adipokines in offspring, even
if they were not obese or diabetic. Additional studies are
warranted to evaluate whether such preclinical alterations in
adipokine levels presage future risk of obesity or DM.
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Figure 2. Adiponectin and RBP4 levels expressed as multivariable adjusted least squares geometric mean and 95% conﬁdence interval error
bars (y-axis) according to the presence or absence of parental diabetes mellitus before age 60 years (x-axis).
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